Introduction
============

With 10.4 million new cases of active tuberculosis (TB) in 2016, TB remains one of the world's biggest health threats \[[@r1]\]. Most countries in the European Union (EU) are low-incidence countries where TB predominantly affects vulnerable populations such as migrants, prisoners and people living with HIV \[[@r2]\]. To achieve an ongoing decrease in TB incidence in EU countries, further efforts are needed to address these often hard-to-reach groups \[[@r2]\]. In Germany, 5,915 cases of active TB were notified in 2016 \[[@r3]\]. Demographic changes and migration influence TB incidence in Germany and contributed to the end of a previously declining TB trend \[[@r3],[@r4]\]. Ensuring early detection and comprehensive access of all population groups to timely and complete treatment will be essential to control TB and ultimately meet the World Health Organization's (WHO) TB elimination goals \[[@r5]\].

Cases found by passive case finding, i.e. TB patients diagnosed after clinical presentation with symptoms or post mortem, contributed the highest proportion of new cases in 2016 (66%) \[[@r3]\]. Sixteen per cent of cases had been diagnosed by active case finding among asylum seekers and refugees \[[@r3]\]. This proportion was on average 2.4% between 2002 and 2014 and had been increasing since 2008, when it was smallest (0.7%) \[[@r3]\]. Active case finding is performed among several risk groups to ensure early detection and treatment and to prevent further transmission from infectious cases. In recently exposed persons, contact tracing is performed according to German contact tracing recommendations \[[@r6]\]. Among asylum seekers, screening is performed to find infectious pulmonary TB cases early at admission to shared accommodations (reception centres) after entering the country. Screening for infectious pulmonary TB at entry to such shared accommodations is mandatory according to §36.4 of the Protection Against Infection Act (Infektionsschutzgesetz (IfSG)). With the increasing number of migrants seeking asylum in Germany, the mandatory screening for infectious pulmonary TB among asylum seekers has challenged local public health authorities (LPHA) in 2014 and 2015 \[[@r7]-[@r11]\].

TB diagnosis -- upon screening or clinical presentation -- needs to be followed by rapid initiation of an effective and complete treatment to prevent further transmission, achieve cure and prevent the development of secondary drug resistance \[[@r12]\]. Tuberculosis treatment outcome monitoring is an essential part of TB surveillance and key for evaluating the effectiveness of TB screening and care. In line with international requirements \[[@r1],[@r2]\], the German TB notification system comprises the treatment outcome categories *cured, treatment completed, died, treatment failure, treatment default, still on treatment, transfer out, missing* and *unable to determine* ([Table 1](#t1){ref-type="table"}). Treatment outcome is measured after 12 months follow-up and after 24 months for multidrug-resistant TB (MDR-TB) cases. The WHO and the Stop TB Partnership set the target of 90% treatment success (i.e. cured and treatment completed) for all TB cases that require treatment \[[@r1],[@r13]\].

###### Tuberculosis treatment outcome categories in the national notification system, Germany, 2002--2014

  Categories             Definitions
  ---------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------
  Cured                  Treatment completed and culture-negative samples taken at the end of the full course treatment and on at least one previous occasion
  Treatment completed    Treatment completed without evidence of failure but no tests were performed or no result was available at the end of the full course of treatment
  Died                   Death before cure or treatment completion, irrespective of cause
  Treatment failure      Culture or sputum smear remaining positive or becoming positive again 5 months or more into the course of treatment
  Treatment default^a^   Treatment interrupted for at least 2 consecutive months
  Still on treatment     Patient still on treatment at 12 months (and at 24 months for multidrug-resistant (MDR) TB cases) without any other outcome during treatment
  Transfer out           Patient referred to a known or unknown address and information on outcome not available
  Missing                Information on treatment outcome is missing (empty field)
  Unable to determine    Information on treatment outcome could not be obtained by the local public health authority

**^a^**'Treatment default' is the translation of the German category name 'Abbruch der Behandlung'. Internationally, the previously used term 'defaulter' has recently been replaced by 'lost to follow-up', but this is not reflected in the German TB surveillance system.

To what extent pulmonary TB found among screened asylum seekers in Germany is followed up until treatment completion, remains unclear however. We therefore aimed to assess whether TB cases identified by screening among asylum seekers had an equally successful and completely reported treatment outcome as those diagnosed by passive case finding and by contact tracing, in order to highlight potential gaps in surveillance and case management.

Methods
=======

Data source
-----------

We used case-based national TB notification data from Germany, reported to the Robert Koch Institute (RKI) through the electronic reporting system SurvNet\@RKI \[[@r14]\]. Date of data extraction was 1 March 2016.

We included in our analysis pulmonary TB cases notified between 2002 and 2014 with available information on age and sex (total n = 52,995). The dataset was further restricted to cases that were identified by the following modes of case finding: (i) screening of asylum seekers, (ii) passive case finding and (iii) contact tracing (total n = 44,084). The notification system, case definitions for TB and diagnostic procedures have remained largely unchanged over the investigation period.

Definitions
-----------

For German national disease surveillance, a case of TB is defined by clinical diagnosis of TB by a physician followed by the decision to initiate a full course of anti-tuberculosis treatment, with or without bacteriological confirmation or epidemiological link \[[@r15]\]. Bacteriological confirmation refers to a culture of *Mycobacterium tuberculosis* complex, or a combination of a positive microscopy result for acid-fast bacilli with a positive nucleic acid amplification test (NAAT) for the same specimen type \[[@r15]\]. In the TB notification system, information on the patients' age, sex, country of birth and the mode of case finding is recorded, as is bacteriological testing including drug resistance, previous TB diagnosis, site of TB and treatment outcome at any time of follow-up, in this study set to at least 12 months \[[@r16]\].

Modes of case finding are defined by reporting guidelines \[[@r16]\]. Screened asylum seekers are defined as TB cases that were identified by screening asylum seekers according to §36.4 IfSG by chest X-ray (except pregnant women or children younger than 15 years) on admission to a shared accommodation \[[@r17]\]. In children and pregnant women, screening including clinical signs and symptoms and immunological testing with either interferon-γ release assay (IGRA) or tuberculin skin test (TST) is recommended \[[@r17],[@r18]\]. Thus, the screening intended to rule out infectious pulmonary TB also leads to the detection of pulmonary TB with negative bacteriological result. Cases identified by passive case finding are defined as TB cases diagnosed after clinical presentation; TB cases diagnosed post mortem were excluded from our study. Cases identified during the follow-up of exposed persons are defined as cases identified by contact tracing. Cases identified by other active case finding were not considered in this study.

Treatment success and data completeness
---------------------------------------

To assess treatment success and data completeness, we grouped treatment outcomes in three different ways (Group A, B and C) as displayed in [Figure 1](#f1){ref-type="fig"}.
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**Group A**: Cases that were *cured* or had *treatment completed* were referred to as cases with *successful treatment* and compared with cases that were recorded with all other outcomes. This definition is adapted from ECDC classification 2016 \[[@r2]\] and is in line with WHO and the Stop TB Partnership's definitions of treatment outcomes \[[@r1],[@r13]\].

**Group B**: Cases with successful treatment were compared with cases with known non-successful treatment outcomes (*died*, *treatment failure* or *default);* all cases with outcome categories that contained essentially no information on the result of the treatment of the case (*still on treatment, transfer out, missing* and *unable to determine)* were excluded from this comparison in order to disentangle cases with non-successful treatment outcome from cases that were *lost to follow-up*.

**Group C**: Cases with known treatment outcomes, both successful and unsuccessful *(successful treatment, died, treatment failure, treatment default)* were compared with cases that were *lost to follow-up* to the national tuberculosis notification system (*transfer out, missing, unable to determine* or too long *still on treatment*). The classification is based on the assumption that in all these cases, LPHA did presumably not have up-to-date information and could not ascertain the treatment outcome. 'Too long' *still on treatment* was defined as cases without MDR-TB who were notified as *still on treatment* more than 24 months after notification and MDR-TB cases who were notified as *still on treatment* more than 36 months after notification. The remaining cases notified as *still on treatment* were defined as cases with known outcome as still on treatment is valid information on the treatment status.

Data analysis and protection
----------------------------

We describe demographic information, i.e. age (continuous), sex (female vs male), country of birth (Germany vs WHO regions excluding Germany vs unknown), as well as clinical information, i.e. MDR (not applicable, no drug susceptibility test (DST) reported, DST reported and among those with DST: not MDR vs MDR), previous TB diagnosis (no vs yes vs unknown), infectiousness (respiratory specimen: culture-negative and smear-negative vs culture-positive and smear-negative vs smear-positive vs unknown), severity of disease (pulmonary TB with TB of the central nervous system (CNS), meningitis or disseminated TB vs pulmonary TB only or with other secondary sites vs pulmonary TB with unknown additional manifestations) and treatment outcomes ([Figure 1](#f1){ref-type="fig"}) by mode of case finding.

We also describe the above characteristics by treatment outcome. For categorical variables, we present numbers and proportions, for continuous variables, median and interquartile range (IQR).

The associations between mode of case finding and treatment outcome or loss to follow-up were investigated with multivariable logistic regression analyses using the passive case finding group as reference group. We interpreted coefficients in terms of odds ratios (OR) and report 95% confidence intervals (CI). We designed three logistic regression models (A, B, C) with different dependent variables: one for each group (A, B, C) of treatment outcome and loss to follow-up ([Figure 1](#f1){ref-type="fig"}). We included mode of case finding as the independent variable and the following potential confounders (as described above if not specified) in all three models: age (in groups of 15 years), sex, country of birth (simplified: Germany vs other vs unknown), drug resistance (simplified: not MDR, MDR, unknown), infectiousness, previous TB and severity of disease, as well as reporting period (2002--05 vs 2006--14) as changes in data plausibility checks and completeness checks were introduced in 2006.

Analyses were conducted with STATA version 14 (Stata corporation, Texas, United States).

All investigated data were anonymous and collected within the legal framework of the IfSG.

Results
=======

The cases' demographic and clinical characteristics stratified by mode of case finding are presented in [Table 2](#t2){ref-type="table"}.

###### Demographic and clinical characteristics of pulmonary tuberculosis cases notified by mode of case finding, Germany, 2002--2014 (n = 44,084)

  Characteristics of cases                           Active case finding                          Passive case finding                                        
  -------------------------------------------------- -------------------------------------------- ---------------------- ------- --------- -------- --------- ----
  **Demographic characteristics**                                                                                                                             
  Median age in years (IQR)                          28                                           (22-37)                27      (11-44)   50       (34-68)   
  Sex                                                                                                                                                         
  Female                                             336                                          23                     1,628   45        14,373   37        
  Male                                               1,138                                        77                     1,963   55        24,646   63        
  Place of birth                                                                                                                                              
  Germany                                            6                                            0.4                    2,312   64        21,420   55        
  Other country                                      WHO Region Europe without Germany            539                    37      773       21       10,156    26
  WHO Region Eastern Mediterranean                   377                                          26                     104     2.9       1,682    4.3       
  WHO Region Africa                                  320                                          22                     84      2.3       1,722    4.4       
  WHO Region South-East Asia                         46                                           3.1                    74      2.1       1,345    3.4       
  WHO Region Western Pacific                         82                                           5.6                    58      1.6       997      2.6       
  WHO Region Americas                                4                                            0.3                    11      0.3       266      0.7       
  Unknown country                                    100                                          6.8                    175     4.9       1,431    3.7       
  **Clinical characteristics**                                                                                                                                
  Infectiousness                                                                                                                                              
  Culture-negative, smear-negative                   496                                          34                     1,164   32        6,268    16        
  Culture-positive, smear-negative                   498                                          34                     1,417   39        12,737   33        
  Smear-positive                                     410                                          28                     748     21        18,966   49        
  Unknown                                            70                                           4.7                    262     7.3       1,048    2.7       
  Previous TB                                                                                                                                                 
  No                                                 876                                          59                     3,252   91        29,963   77        
  Yes                                                201                                          14                     109     3.0       4,429    11        
  Unknown                                            397                                          27                     230     6.4       4,627    12        
  Drug resistance                                                                                                                                             
  Drug susceptibility test (DST reported)            838                                          57                     2,037   57        28,950   74        
  Not MDR (% of DST reported)                        747                                          89                     2,004   98        28,388   98        
  MDR (% of DST reported)                            91                                           11                     33      1.6       562      1.9       
  Unknown                                            Not applicable; bacteriologically negative   486                    33      1,129     31       6,075     16
  No drug susceptibility test reported               150                                          10                     425     12        3,994    10        
  Severity of disease                                                                                                                                         
  Exclusively pulmonary TB                           1,173                                        80                     3,081   86        32,620   84        
  Pulmonary and CNS, meningitis or disseminated TB   5                                            0.3                    10      0.3       574      1.5       
  Unknown                                            296                                          20                     500     15        5,825    15        

CNS: central nervous system; DST: drug susceptibility test; MDR: multidrug-resistant; TB: tuberculosis; WHO: World Health Organization.

Cases identified by screening asylum seekers (n = 1,474) were of similar median age with a smaller IQR compared with cases identified by contact tracing (n = 3,591) (28 vs 27 years) and were less often female (23% vs 45%). They had a similar proportion of culture- and smear-negative cases (34% vs 32%), more often unknown information about previous TB (27% vs 6.4%) and more often MDR-TB (11% vs 1.6%) ([Table 2](#t2){ref-type="table"}). Compared with cases identified by passive case finding (n = 39,019), the cases identified by screening asylum seekers had a lower median age (28 vs 50 years), a lower proportion of females (23% vs 37%) and a higher proportion of culture- and smear-negative cases (34% vs 16%), of unknown information about previous TB (27% vs 12%) and of MDR-TB (11% vs 1.9%) ([Table 2](#t2){ref-type="table"}).

Treatment success was highest among pulmonary TB cases identified by contact tracing (87%; 3,139/3,591), followed by cases identified by passive case finding (74%; 28,804/39,019) and by screening asylum seekers (60%; 884/1,474) ([Figure 2](#f2){ref-type="fig"}).
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The largest proportion of missing and indeterminate data on treatment outcome was among cases identified by screening asylum seekers (22%; 329/1,474), followed by patients identified by passive case finding (7.9%; 3,076/39,019) and contact tracing (6.3%; 225/3,591) ([Figure 2](#f2){ref-type="fig"}).

Detailed analyses showed that the proportion of successful outcomes among all outcomes (Group A, [Figure 1](#f1){ref-type="fig"}) varied not only by the mode of case finding but also by age, sex, place of birth, infectiousness, previous TB diagnosis treatment, drug resistance, severity of disease and changes in data plausibility and completeness checks ([Table 3](#t3){ref-type="table"}).

###### Demographic and clinical characteristics of notified pulmonary tuberculosis cases by treatment outcome, Germany, 2002--2014 (n = 44,084)

  Characteristics of cases                                                       Group A: successful outcomes (n) among all outcomes (N)   Group B: successful outcomes (n) among known outcomes (N)   Group C: known outcomes (n) among all outcomes (N)                                                         
  ------------------------------------------------------------------------------ --------------------------------------------------------- ----------------------------------------------------------- ---------------------------------------------------- -------- -------- -------- -------- -------- -------- ----
  **Main exposure of interest**                                                                                                                                                                                                                                                                                   
  Mode of case finding                                                                                                                                                                                                                                                                                            
  Passive case finding                                                           28,804                                                    39,019                                                      74                                                   28,804   34,766   83       35,214   39,019   90       
  Contact tracing                                                                3,139                                                     3,591                                                       87                                                   3,139    3,285    96       3,334    3,591    93       
  Screening asylum seekers                                                       884                                                       1,474                                                       60                                                   884      983      90       1,062    1,474    72       
  **Demographic characteristics**                                                                                                                                                                                                                                                                                 
  Age in years                                                                                                                                                                                                                                                                                                    
  \< 15                                                                          1,611                                                     1,782                                                       90                                                   1,611    1,634    99       1,654    1,782    93       
  15--29                                                                         6,329                                                     7,874                                                       80                                                   6,329    6,645    95       6,777    7,874    86       
  30--44                                                                         8,256                                                     10,322                                                      80                                                   8,256    8,959    92       9,105    10,322   88       
  45--59                                                                         7,536                                                     9,674                                                       78                                                   7,536    8,652    87       8,769    9,674    91       
  60--74                                                                         5,649                                                     8,070                                                       70                                                   5,649    7,342    77       7,432    8,070    92       
  ≥ 75                                                                           3,446                                                     6,362                                                       54                                                   3,446    5,802    59       5,873    6,362    92       
  Sex                                                                                                                                                                                                                                                                                                             
  Female                                                                         12,699                                                    16,337                                                      78                                                   12,699   14,557   87       14,761   16,337   90       
  Male                                                                           20,128                                                    27,747                                                      73                                                   20,128   24,477   82       24,849   27,747   90       
  Place of birth                                                                                                                                                                                                                                                                                                  
  Germany                                                                        17,337                                                    23,738                                                      73                                                   17,337   21,653   80       21,950   23,738   92       
  Other country                                                                  WHO Region Europe                                         8,850                                                       11,468                                               77       8,850    10,077   88       10,192   11,468   89
  WHO Region Eastern Mediterranean                                               1,701                                                     2,163                                                       79                                                   1,701    1,848    92       1,892    2,163    87       
  WHO Region Africa                                                              1,675                                                     2,126                                                       79                                                   1,675    1,794    93       1,819    2,126    86       
  WHO Region South-East Asia                                                     1,141                                                     1,465                                                       78                                                   1,141    1,233    93       1,252    1,465    85       
  WHO Region Western Pacific                                                     886                                                       1,137                                                       78                                                   886      955      93       970      1,137    85       
  WHO Region Americas                                                            232                                                       281                                                         83                                                   232      244      95       248      281      88       
  Unknown country                                                                1,005                                                     1,706                                                       59                                                   1,005    1,230    82       1,287    1,706    75       
  **Clinical characteristics**                                                                                                                                                                                                                                                                                    
  Infectiousness                                                                                                                                                                                                                                                                                                  
  Culture-negative, smear-negative                                               6,128                                                     7,928                                                       77                                                   6,128    7,118    86       7,288    7,928    92       
  Culture-positive, smear-negative                                               11,035                                                    14,652                                                      75                                                   11,035   13,089   84       13,212   14,652   90       
  Smear-positive                                                                 14,806                                                    20,124                                                      74                                                   14,806   17,750   83       17,984   20,124   89       
  Unknown                                                                        858                                                       1,380                                                       62                                                   858      1,077    80       1,126    1,380    82       
  Previous TB                                                                                                                                                                                                                                                                                                     
  No                                                                             26,433                                                    34,091                                                      77                                                   26,433   30,690   86       31,090   34,091   91       
  Yes                                                                            3,188                                                     4,739                                                       67                                                   3,188    4,132    77       4,193    4,739    88       
  Unknown                                                                        3,206                                                     5,254                                                       61                                                   3,206    4,212    76       4,327    5,254    82       
  Drug resistance                                                                                                                                                                                                                                                                                                 
  Not MDR                                                                        24,034                                                    31,139                                                      77                                                   24,034   28,066   86       28,214   31,139   91       
  MDR                                                                            399                                                       686                                                         58                                                   399      505      79       536      686      78       
  Unknown                                                                        Not applicable; bacteriologically negative                5,963                                                       7,690                                                77       5,963    6,930    86       7,089    7,690    92
  No drug susceptibility test reported                                           2,431                                                     4,569                                                       53                                                   2,431    3,533    69       3,762    4,569    82       
  Severity of disease                                                                                                                                                                                                                                                                                             
  Exclusively pulmonary TB                                                       28,163                                                    36,874                                                      76                                                   28,163   33,114   85       33,583   36,874   91       
  Pulmonary and CNS, meningitis or disseminated TB                               342                                                       589                                                         58                                                   342      520      66       527      589      89       
  Unknown                                                                        4,322                                                     6,621                                                       65                                                   4,322    5,400    80       5,500    6,621    83       
  **Time period based on change of data plausibility and completeness checks**                                                                                                                                                                                                                                    
  2002--05                                                                       12,594                                                    17,310                                                      73                                                   12,594   14,978   84       15,251   17,310   88       
  2006--14                                                                       20,233                                                    26,774                                                      76                                                   20,233   24,056   84       24,359   26,774   91       

CNS: central nervous system; DST: drug susceptibility test; MDR: multidrug-resistant; TB: tuberculosis; WHO: World Health Organization.

Treatment success (Group A) was particularly low among TB cases who had no DST reported (53%; 2,431/4,569), were 75 years or older (54%; 3,446/6,362), had MDR-TB (58%; 399/686), a severe TB manifestation (CNS, meningitis or disseminated) in addition to pulmonary TB (58%; 342/589), unknown place of birth (59%; 1,005/1,706) or were identified by screening asylum seekers (60%; 884/1,474) ([Table 3](#t3){ref-type="table"}).

Analysis adjusted for demographic and clinical characteristics showed that mode of case finding was independently associated with treatment success (Model A, [Figure 1](#f1){ref-type="fig"}, [Table 4](#t4){ref-type="table"}). It indicated 2.4 times higher odds of non-successful treatment for cases identified by screening asylum seekers compared with cases identified by passive case finding; cases identified by contact tracing showed 0.64 times lower odds of non-successful treatment outcomes compared with passive case finding ([Table 4](#t4){ref-type="table"}).

###### Notified pulmonary tuberculosis cases - multivariable analyses for the association between the mode of case finding and treatment outcome, Germany, 2002--2014 (n = 44,084)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics of cases                                                       Model A: success\               Model B: success\                 Model C: known outcome\                                                              
                                                                                 (0) vs all other outcomes (1)   (0) vs no treatment success (1)   (0) vs loss to follow-up (1)                                                         
  ------------------------------------------------------------------------------ ------------------------------- --------------------------------- ------------------------------ ------- -------------- ---------- ------ ------------ ----------
  **Main exposure of interest**                                                                                                                                                                                                         

  Mode of case finding                                                                                                                                                                                                                  

  Passive case finding                                                           Ref                             Ref                               Ref                                                                                  

  Contact tracing                                                                0.64                            0.57--0.71                        \< 0.001                       0.54    0.45--0.65     \< 0.001   0.73   0.63--0.84   \< 0.001

  Screening asylum seekers                                                       2.37                            2.11--2.67                        \< 0.001                       1.38    1.10--1.73     0.006      2.35   2.06--2.68   \< 0.001

  **Demographic characteristics**                                                                                                                                                                                                       

  Age in years                                                                                                                                                                                                                          

  \< 15                                                                          Ref                             Ref                               Ref                                                                                  

  15--29                                                                         1.84                            1.54--2.20                        \< 0.001                       3.06    1.98--4.73     \< 0.001   1.41   1.15--1.74   \< 0.001

  30--44                                                                         1.90                            1.59--2.26                        \< 0.001                       4.79    3.13--7.34     \< 0.001   1.25   1.02--1.54   0.030

  45--59                                                                         2.11                            1.77--2.51                        \< 0.001                       7.43    4.86--11.35    \< 0.001   1.06   0.86--1.30   0.571

  60--74                                                                         3.09                            2.59--3.68                        \< 0.001                       14.53   9.52--22.19    \< 0.001   0.84   0.68--1.04   0.116

  ≥ 75                                                                           6.39                            5.35--7.63                        \< 0.001                       34.15   22.36--52.16   \< 0.001   0.82   0.66--1.02   0.081

  Sex                                                                                                                                                                                                                                   

  Female                                                                         Ref                             Ref                               Ref                                                                                  

  Male                                                                           1.33                            1.26--1.39                        \< 0.001                       1.52    1.42--1.62     \< 0.001   1.07   1.00--1.14   0.049

  Place of birth                                                                                                                                                                                                                        

  Germany                                                                        Ref                             Ref                               Ref                                                                                  

  Other country                                                                  0.90                            0.85--0.94                        \< 0.001                       0.70    0.65--0.75     \< 0.001   1.34   1.25--1.45   \< 0.001

  Unknown country                                                                1.81                            1.61--2.03                        \< 0.001                       0.94    0.80--1.12     0.494      3.10   2.72--3.53   \< 0.001

  **Clinical characteristics**                                                                                                                                                                                                          

  Infectiousness                                                                                                                                                                                                                        

  Culture-negative, smear-negative                                               Ref                             Ref                               Ref                                                                                  

  Culture-positive, smear-negative                                               2.58                            2.35--2.84                        \< 0.001                       2.35    2.08--2.65     \< 0.001   2.19   1.91--2.50   \< 0.001

  Smear-positive                                                                 2.79                            2.55--3.05                        \< 0.001                       2.54    2.27--2.85     \< 0.001   2.31   2.04--2.62   \< 0.001

  Unknown                                                                        2.12                            1.86--2.41                        \< 0.001                       1.64    1.37--1.97     \< 0.001   2.43   2.06--2.87   \< 0.001

  Previous TB treatment                                                                                                                                                                                                                 

  No                                                                             Ref                             Ref                               Ref                                                                                  

  Yes                                                                            1.20                            1.12--1.29                        \< 0.001                       1.18    1.08--1.28     \< 0.001   1.23   1.11--1.36   0.003

  Unknown                                                                        1.90                            1.78--2.03                        \< 0.001                       1.84    1.69--1.97     \< 0.001   1.73   1.59--1.88   \< 0.001

  Drug resistance                                                                                                                                                                                                                       

  No MDR                                                                         Ref                             Ref                               Ref                                                                                  

  MDR                                                                            2.83                            2.40--3.32                        \< 0.001                       3.03    2.40--3.83     \< 0.001   1.89   1.56--2.30   \< 0.001

  Unknown                                                                        2.76                            2.56--2.98                        \< 0.001                       2.56    2.33--2.81     \< 0.001   1.83   1.65--2.02   \< 0.001

  Severity of disease                                                                                                                                                                                                                   

  Exclusively pulmonary TB                                                       Ref                             Ref                               Ref                                                                                  

  Pulmonary and CNS, meningitis or disseminated TB                               2.51                            2.10--2.99                        \< 0.001                       3.25    2.63--4.00     \< 0.001   1.23   0.94--1.62   0.125

  Unknown                                                                        1.48                            1.40--1.58                        \< 0.001                       1.24    1.15--1.35     \< 0.001   1.83   1.70--1.98   \< 0.001

  **Time period based on change of data plausibility and completeness checks**                                                                                                                                                          

  2002--05                                                                       Ref                             Ref                               Ref                                                                                  

  2006--14                                                                       0.91                            0.86--0.95                        \< 0.001                       1.04    0.98--1.10     0.228      0.75   0.70--0.80   \< 0.001
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

aOR: adjusted odds ratio; CI: confidence interval; CNS: central nervous system; MDR: multidrug-resistant; TB: tuberculosis.

Restricting analysis of treatment outcomes to cases with known outcomes (Group B, [Figure 1](#f1){ref-type="fig"}) and comparing successful and non-successful treatment among them, treatment success was particularly low for cases  aged 75 years or older (59%; 3,446/5,802), with severe manifestation in addition to pulmonary TB (66%; 342/520) and cases that had no DST reported (69%; 2,431/3,533) ([Table 3](#t3){ref-type="table"}). While cases identified by screening asylum seekers had higher treatment success (90%; 884/983) than cases identified by passive case finding (83%; 28,804/34,766) in the descriptive analysis of Group B, adjusted analysis indicated 1.4 times higher odds for a non-successful treatment outcome for cases identified by screening asylum seekers compared with cases identified by passive case finding (Model B, [Table 4](#t4){ref-type="table"}). In addition, older age, MDR-TB, severe manifestations and infectiousness were associated with particularly high odds of unsuccessful treatment outcome in Model B ([Table 4](#t4){ref-type="table"}).

Analysis of loss to follow-up (Group C) showed that the proportion of known outcomes among all possible treatment outcomes was lowest among cases identified by screening asylum seekers (72%; 1,062/1,474), followed by cases with unknown place of birth (75%; 1,287/1,706) and cases with MDR (78%; 536/686) ([Table 3](#t3){ref-type="table"}). Adjusted analysis indicated 2.3 times higher odds for loss to follow-up among cases identified by screening asylum seekers compared with cases identified by passive case finding; cases identified by contact tracing showed 27% lower odds of loss to follow-up compared with passive case finding (Model C, [Table 4](#t4){ref-type="table"}). Apart from identification by screening asylum seekers, cases with unknown place of birth and unknown drug resistance showed particularly high odds of getting lost to follow-up ([Table 4](#t4){ref-type="table"}).

Discussion
==========

With our study, we aimed to assess treatment outcomes of pulmonary TB cases identified by screening asylum seekers. We found that cases identified by screening asylum seekers -- unlike cases identified by contact tracing -- had significantly poorer treatment outcomes and higher odds of loss to follow-up compared with cases identified by passive case finding after adjustment for demographic and clinical characteristics.

Cases identified by screening asylum seekers were similar to those identified by contact tracing in terms of age, infectiousness and severity of disease but were more likely to have MDR-TB or a history of previous TB diagnosis. Compared with cases identified by passive case finding, those among screened asylum seekers were younger, more often male and less infectious.

Our study results corroborate previous findings that TB screening by chest X-ray, as used for asylum seekers, allowed early detection of cases that were still smear-negative \[[@r19]-[@r22]\]. Thus screening has the potential to prevent transmission and facilitate early treatment initiation. The high proportion of bacteriologically negative pulmonary TB cases (34%) raises the issue of potential overdiagnosis of TB by chest X-ray screening. However, TB cases identified by contact tracing were equally often bacteriologically negative, and the detection of bacteriologically negative TB is considered beneficial given the high risk of developing infectious TB if untreated \[[@r23]\]. In addition, screened asylum seekers were more likely to have had a diagnosis of MDR-TB or a positive or unknown history of previous TB compared with cases identified by passive case finding. Contributing factors may include higher rates of TB and MDR-TB in their country of birth \[[@r1]\] and fragmented healthcare services in countries of origin leading to treatment interruptions \[[@r24]\]. Of note, DST results, which are strongly warranted for treatment decisions, were frequently unavailable.

With 60% treatment success (Group A) among pulmonary TB cases identified by screening asylum seekers, 74% among those identified by passive case finding and 87% among those identified by contact tracing, none of the groups met the target of 90% treatment success \[[@r1],[@r13]\]. However, the odds for non-successful treatment were substantially higher for cases identified by screening asylum seekers and markedly lower for cases identified by contact tracing compared to the cases identified by passive case finding (adjusted for other known confounders).

While asylum seeker status was independently associated with an unsuccessful treatment outcome, this was not true for reporting a foreign country of birth, which had lower odds of non-successful treatment outcomes (Model A). Other studies also found poorer treatment adherence for migrants with insecure legal status \[[@r25]\] and those that had arrived recently \[[@r26]\], but did not find an independent negative impact of foreign country of origin. Our findings contrast with a recent analysis of European data that found poorer treatment outcomes for foreign-born cases; however, that study could not distinguish between legal status and country of birth \[[@r27]\].

The magnitude of association between known clinical risk factors and non-successful treatment outcomes was greater when unknown outcomes were excluded from the analysis (Model B). In accordance with previous knowledge \[[@r20],[@r27],[@r28]\], increasing age, a proxy for co-morbidities and risk of dying, strongly increased the odds of non-successful treatment in model B. In addition, the odds for MDR-TB and severe disease manifestations were greater among those with negative treatment outcomes in model B compared with model A, in coherence with previous studies \[[@r20],[@r29]-[@r32]\].

In our study, being identified by screening asylum seekers was also independently associated with being lost to follow-up after adjustment for potential confounders. Reasons for loss to follow-up can include the patient's decision to stop treatment without informing treatment facilities \[[@r33]\]. A potential explanation for this may be the lack of perceived illness \[[@r34]\] that might be more pronounced in cases identified by screening who had no symptoms. That patients identified by contact tracing were 27% less likely to be lost to follow-up than patients identified by passive case finding, however, indicates that even asymptomatic patients can be successfully followed up. Geographical distance to TB-treatment facilities, a trusting and supportive provider--patient relationship as well as security of legal status have been found to be predictors for treatment adherence \[[@r25],[@r34]-[@r36]\]. The reduction of structural barriers to TB diagnosis and treatment including availability of free, accessible and culturally appropriate health services for vulnerable groups such as migrants has been shown to be a key element in increasing treatment success \[[@r36]\]. Potential structural barriers to TB treatment completion and reasons for loss to follow-up in Germany include limited access to care and interpreters \[[@r7]\], (forced) relocations of asylum seekers within Germany or to other countries during treatment \[[@r7],[@r11],[@r33]\] and changing administrative authorities handling the case \[[@r10]\].

Limitations
-----------

Our investigation was based on national notification data, and under- or overestimation of the true case number owing to under-diagnosis and under-reporting or to double-reporting cannot be entirely excluded. In addition, incomplete information for notified cases at the national level may reflect unavailable data at the treatment facility or at the LPHA level. Non-reported treatment outcome cannot entirely be disentangled from non-completed treatment in our data. The TB patient may have completed treatment within the remit of a different health authority than the one that received the initial notification, or under the supervision of a doctor or hospital that has missed to report the treatment outcome to the local health authority.

Based on the available variables in the notification data, our analysis could only compare 'asylum seekers identified by screening' with cases identified by other modes of case finding. However, cases identified by other modes of case finding may also be asylum seekers. Furthermore, incorrect classification of the mode of case finding cannot be excluded.

Full information on tuberculosis treatment outcome becomes available only 1 year after the reporting year and our study therefore includes cases notified up to and including 2014. Whether characteristics and treatment outcomes of cases notified from 2002 to 2014 can be extrapolated to cases notified later is unknown and will require evaluation. Increasing workload at LPHA level caused by increasing case numbers (by nearly 30% in 2015 \[[@r3]\]) may affect the follow-up of cases and completion of information.

Conclusion
==========

The low proportion of smear-positive TB suggests that asylum seekers were found early by screening; a good starting point for successful treatment. However, they were often lost to follow-up and had poorer treatment outcomes than cases identified by passive case finding or contact tracing.

The documentation of mode of case finding in German TB notification data proved useful for the evaluation of group-specific treatment outcomes, namely screened asylum seekers. We recommend a standardised approach to reporting of case finding information across Europe to allow evaluation of treatment success and comparison across countries by modes of case finding. Regarding treatment outcome data, we need to better disentangle non-reported treatment outcomes from reporting incomplete course of treatment and to address both issues individually to obtain high treatment success.

Increased case detection by screening can only unfold its health benefits when detected tuberculosis is effectively treated and reliably cured. Tuberculosis screening activities among asylum seekers can be a door to access general medical care. TB screening at admission to reception centres may also reduce TB exposure and reduce the need for resource-intensive contact investigations in these settings.

While specific reasons for the higher odds of non-successful treatment among asylum seekers in Germany need to be studied further, available research suggests that patients need to be better linked to treatment facilities and structural barriers to treatment completion need to be addressed to secure screening benefits for asylum seekers and the communities.
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